Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks
to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who
failed to one line or more than one line of small molecule kinase inhibitor or
well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase
inhibitor or chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Changhua Christian Hospital China Medical University Hospital Kaohsiung Medical University Chung-Ho Memorial Hospital Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital